ArticleTranslational lung cancer research2021

Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV.

Wolfgang M Brueckl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.